Buchholz Lab new manuscript alert! 🚨 This time with me as a first author! 🥳 Read the thread bellow for a short summary of the work! 🧵 academic.oup.com/nar/advance-ar…

Gene therapy that alters hemoglobin genes may cure blood diseases that afflict millions of individuals. Scientists at St. Jude and Broad Institute used potentially curative base editing technology to restart fetal hemoglobin production in patient cells. bit.ly/434cpGB

Excited to share my first last Author paper. Out now in Genome Biology We Buchholz Lab report two new methods. To evolve CRISPR-Cas systems (CaSLiDE) and to screen thousands of variants at once (DEQSeq) Thanks to the amazing team of co-authors! genomebiology.biomedcentral.com/articles/10.11…

🧬 Exciting news! Don't miss our latest publication introducing DEQSeq, a groundbreaking nanopore sequencing method for genome editing enzyme selection from evolved variants. Great job, Lukas T. Schmitt, and all the co-authors!👏🏻 #DEQSeq #GenomeEditing genomebiology.biomedcentral.com/articles/10.11…

#Breaking: The UK Medicines and Healthcare products Regulatory Agency (MHRA) approves our CRISPR/Cas9 gene-edited treatment for #SickleCellDisease and #BetaThalassemia in Great Britain—a historic scientific milestone. Learn more: vrtx.com/?utm_source=co…

🎉I am thrilled to announce that my PhD thesis work got published in Nature Biotechnology today! Grateful to all co-authors from Buchholz Lab and @seamlesstx.🧬We developed zinc finger DNA-binding dependent site-specific recombinases. nature.com/articles/s4158… See the thread below:

Fabulous news 🥳 Today we report in Nature Biotechnology a new method combining the power of designer-recombinases with zinc-finger domain insertions for precise and adaptable genome editing tools. Huge congrats Liliya Mukhametzyanova on her first “first author” paper 👏🎉 rdcu.be/dxrtp

🌟Excited to share that Manavi Jain from our lab is attending #ASGCT2024 in Baltimore. Check out her poster #1184 tomorrow to learn more about evolving designer recombinases for treating ß-hemoglobinopathies🧬🩸 SaxoCell ASGCT

It was an absolute pleasure to attend #ASGCT2024. I got to present a poster about my ongoing PhD work on using designer recombinases for treating ß-hemoglobinopathies. Great discussions and groundbreaking research made it a truly memorable experience! Buchholz Lab SaxoCell

1/ 🎉 🧬I’m excited to share our latest publication exploring Cre recombinase loxP spacer specificity and reprogramming Cre variants with altered spacer specificity. Nucleic Acids Res 🔬 Buchholz Lab 🧬 academic.oup.com/nar/advance-ar…